转移性去势抵抗性前列腺癌镭-223治疗的实用建议
本文基于对六个国家11个核医学中心镭-223治疗流程的观察与关键人员访谈,经专家会议形成共识建议,涵盖中心组织与准备、患者转诊、镭-223订购、准备与处置、治疗实施及患者体验,旨在补充现有管理指南并优化镭-223服务。
要点
- 建议涵盖中心组织与准备、患者转诊、镭-223订购与处置、治疗实施及患者体验。
- 指导包括中心内及多学科团队的结构化协调与沟通,聚焦分享最佳实践。
- 这些专家建议旨在补充现有管理指南,帮助核医学中心优化镭-223服务。
核心结论
- 这些专家建议旨在补充现有管理指南,分享最佳实践和经验将帮助核医学中心优化镭-223服务提供并改善患者照护。
研究设计与样本
- 独立研究咨询机构观察镭-223操作流程,并对来自六个国家(德国、意大利、荷兰、西班牙、瑞士和英国)11个有镭-223给药经验的核医学中心所有关键工作人员进行访谈。
- 研究结果在这些中心专家会议上汇总讨论,并定义了关键共识建议。
主要发现
- 建议覆盖中心组织与准备、患者转诊、镭-223订购、准备与处置、镭-223治疗实施/给药以及患者体验。
- 指导包括中心内和多学科团队的结构化协调与沟通,聚焦于分享最佳实践以在整个治疗路径中提供高质量、以患者为中心的照护。
关键数值与推荐
- 原文未报告具体推荐等级、剂量、阈值或量化标准。
临床怎么用
- 原文未据此给出具体临床推荐,仅指出这些专家建议旨在补充现有管理指南,分享最佳实践和经验将帮助核医学中心优化镭-223服务提供并改善患者照护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision. METHODS: An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined. RESULTS: The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway. CONCLUSIONS: These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care.
引用
- Du Y, Carrio I, De Vincentis G, et al. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28631036. doi:10.1007/s00259-017-3756-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。